Am J Cardiovasc Dis. 2017 Dec 20;7(6):134-150. eCollection 2017.

Systemic inhibition of neddylation by 3-day MLN4924 treatment regime does not impair autophagic flux in mouse hearts and brains.

American journal of cardiovascular disease

Casey A Reihe, Nickolas Pekas, Penglong Wu, Xuejun Wang

PMID: 29348974 PMCID: PMC5768871

Abstract

Beyond helping the cell survive from energy starvation via self-eating a portion of cytoplasm, macroautophagy is also capable of targeted removal of defective organelles or cytoplasmic aberrant protein aggregates, thereby playing an important role in quality control in the cell. Impaired or suppressed macroautophagy activity is associated with the progression from a large subset of heart diseases to heart failure and with the development of the vast majority of, if not all, neurodegenerative diseases, the leading causes of death and disability in humans. Hence, a better understanding of the impact of existing and upcoming pharmacotherapies on macroautophagy in the heart and brain will undoubtedly benefit the search for safer and more effective treatment to improve human health. Neddylation is a recently recognized posttranslational modification process that modifies a subset of cellular proteins and is, by virtue of regulating Cullin-RING ligases, essential to ~20% ubiquitin-proteasome system (UPS)-mediated protein degradation. MLN4924 (Pevonedistat), a specific inhibitor of neddylation that promises to become a new anti-malignancy agent, is capable of inhibiting UPS-mediated progression of the cell cycle and activating macroautophagy in cancer cells. However, no reported study has tested the impact of systemic inhibition of neddylation on autophagic activity in a post-mitotic organ such as the heart and brain. This study was conducted to fill this gap. Sixteen GFP-LC3 transgenic mice of mixed sexes were divided equally into either MLN4924-treated or vehicle-treated groups and were treated respectively with MLN4924 (30 mg/kg,

Keywords: MLN4924; NEDD8 activating enzyme inhibitor; Neddylation; brain; heart; macroautophagy; mice; p62/SQUSTM1

Conflict of interest statement

References

1. Nature. 2009 Apr 9;458(7239):732-6 - PubMed
2. Mol Cell. 2010 Dec 10;40(5):810-22 - PubMed
3. Clin Cancer Res. 2009 Jun 15;15(12 ):3912-6 - PubMed
4. Am J Transl Res. 2010 Jul 21;2(4):390-401 - PubMed
5. Circ Heart Fail. 2013 Sep 1;6(5):1049-57 - PubMed
6. Aging Dis. 2016 Mar 15;7(2):150-62 - PubMed
7. Med Care. 2011 May;49(5):489-95 - PubMed
8. EMBO Rep. 2008 Oct;9(10):969-76 - PubMed
9. Cell. 2010 Feb 5;140(3):313-26 - PubMed
10. Neuro Oncol. 2015 Oct;17 (10 ):1333-43 - PubMed
11. Cell Death Differ. 2005 Nov;12 Suppl 2:1535-41 - PubMed
12. Am J Cardiovasc Dis. 2011;1(3):214-26 - PubMed
13. J Clin Invest. 2014 Jun;124(6):2410-24 - PubMed
14. Invest New Drugs. 2016 Aug;34(4):439-49 - PubMed
15. Cell Death Differ. 2005 Sep;12 (9):1191-7 - PubMed
16. PLoS One. 2014 Jun 24;9(6):e100715 - PubMed
17. J Natl Cancer Inst. 2014 May 22;106(6):dju083 - PubMed
18. Cancer Res. 2010 Dec 15;70(24):10310-20 - PubMed
19. Nat Rev Mol Cell Biol. 2005 Jan;6(1):9-20 - PubMed
20. Biochem Biophys Res Commun. 1993 Aug 31;195(1):393-9 - PubMed
21. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11515-20 - PubMed
22. DNA Repair (Amst). 2010 Dec 10;9(12 ):1229-40 - PubMed
23. Cell Cycle. 2012 Mar 15;11(6):1142-50 - PubMed
24. Circ Res. 2011 Jul 22;109(3):296-308 - PubMed
25. J Mol Cell Cardiol. 2014 Jun;71:16-24 - PubMed
26. Biochim Biophys Acta. 2015 Feb;1852(2):188-94 - PubMed
27. Cell Death Differ. 2018 Feb;25(2):319-329 - PubMed
28. Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2207-19 - PubMed
29. Cell. 1994 Oct 7;79(1):13-21 - PubMed
30. J Biol Chem. 1998 Dec 25;273(52):34983-91 - PubMed
31. Chem Rev. 2009 Apr;109 (4):1561-74 - PubMed
32. Am J Physiol Heart Circ Physiol. 2017 Aug 1;313(2):H304-H319 - PubMed
33. J Cell Sci. 2014 Jan 1;127(Pt 1):3-9 - PubMed
34. Biomol Concepts. 2013 Apr;4(2):161-71 - PubMed
35. Autophagy. 2016;12 (1):1-222 - PubMed
36. Expert Opin Ther Targets. 2011 Mar;15(3):253-64 - PubMed
37. Am J Cardiovasc Dis. 2014 Dec 29;4(4):140-58 - PubMed
38. Circ Res. 2015 Jan 30;116(3):504-14 - PubMed
39. Invest New Drugs. 2017 Feb;35(1):11-25 - PubMed
40. Neuron. 2014 Jan 8;81(1):49-60 - PubMed
41. Cell. 2004 Jul 9;118(1):83-97 - PubMed
42. Circ Res. 2013 Jan 18;112(2):367-81 - PubMed
43. J Mol Cell Cardiol. 2012 Mar;52(3):526-37 - PubMed
44. Oncotarget. 2015 Apr 20;6(11):9002-17 - PubMed
45. J Biol Chem. 2015 Sep 25;290(39):23850-62 - PubMed
46. Neuron. 2003 Oct 9;40(2):427-46 - PubMed
47. Cancer Res. 2012 Jul 1;72(13):3360-71 - PubMed
48. Circulation. 2011 Nov 8;124(19):2117-28 - PubMed
49. Front Physiol. 2017 Aug 17;8:594 - PubMed
50. Physiol Rev. 2002 Apr;82(2):373-428 - PubMed
51. Science. 2008 Feb 15;319(5865):916-9 - PubMed
52. Circ Res. 2015 Nov 6;117(11):956-66 - PubMed
53. Mol Biol Cell. 2004 Mar;15(3):1101-11 - PubMed
54. Neuro Oncol. 2015 Oct;17 (10 ):1305-6 - PubMed
55. Cell Div. 2016 Jun 10;11:8 - PubMed

Publication Types

• Journal Article

Grant support

• R01 HL072166/HL/NHLBI NIH HHS/United States
• R01 HL085629/HL/NHLBI NIH HHS/United States
• R01 HL131667/HL/NHLBI NIH HHS/United States